{"transactions":[{"id":1260071,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":83059,"kind":"person","name":"Rovaldi Christopher","position":1,"cik":"0001706040","reported_name":"Rovaldi Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2025-02-19T16:15:13.000Z","date":"2025-02-18","kind":"grant","planned":false,"acquired":true,"shares":60000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a restricted stock unit (\"RSU\") award.  The RSUs vest as follows: 33% of the RSUs shall vest on February 17, 2026, an additional 34% of the total number of RSUs shall vest on August 15, 2026, and the remaining 33% of the total number of RSUs shall vest on February 16, 2027, in each case, subject to the Reporting Person's Continuous Service (as defined in the 2020 Plan) through each applicable vesting date."}],"balance_after":60000,"source":{"system":"sec-edgar","filing":"0001415889-25-004596","document":"form4-02192025_040205.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1706040/000141588925004596/form4-02192025_040205.xml","form_type":"4"}},{"id":1641004,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":83059,"kind":"person","name":"Rovaldi Christopher","position":1,"cik":"0001706040","reported_name":"Rovaldi Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF OPERATING OFFICER"}}],"security":"Employee Stock Option (right to buy)","published_at":"2024-02-15T20:38:50.000Z","date":"2024-02-13","kind":"grant","planned":false,"acquired":true,"shares":150000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to the option shall vest on February 13, 2025, and 6.25% of the shares subject to the option shall vest in equal quarterly installments thereafter, subject to the Reporting Person continuing to provide service through each such date."}],"balance_after":150000,"derivative":{"exercise_price":56.18,"expiration_date":"2034-02-12","underlying":"Common Stock","underlying_shares":150000},"source":{"system":"sec-edgar","filing":"0001415889-24-004001","document":"form4-02162024_010238.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1706040/000141588924004001/form4-02162024_010238.xml","form_type":"4"}},{"id":2007737,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":83059,"kind":"person","name":"Rovaldi Christopher","position":1,"cik":"0001706040","reported_name":"Rovaldi Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2023-02-17T16:19:18.000Z","date":"2023-02-16","kind":"grant","acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to the option shall vest on February 16, 2024, and 6.25% of the shares subject to the option shall vest in equal quarterly installments thereafter, subject to the Reporting Person continuing to provide service through each such date."}],"balance_after":100000,"derivative":{"exercise_price":54.38,"expiration_date":"2033-02-15","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001209191-23-010591","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1706040/000120919123010591/doc4.xml","form_type":"4"}},{"id":2300353,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":83059,"kind":"person","name":"Rovaldi Christopher","position":1,"cik":"0001706040","reported_name":"Rovaldi Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2022-04-08T16:21:01.000Z","date":"2022-04-06","kind":"exercise","acquired":false,"shares":1728,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"One-fourth (1/4th) of the shares subject to the option vested on January 1, 2021, and one-twelfth (1/12th) of the remaining shares subject to the option shall vest in equal quarterly installments thereafter, subject to the Reporting Person continuing to provide service through each such date."}],"balance_after":8002,"derivative":{"exercise_price":16,"expiration_date":"2030-04-07","underlying":"Common Stock","underlying_shares":1728},"source":{"system":"sec-edgar","filing":"0001209191-22-023860","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1706040/000120919122023860/doc4.xml","form_type":"4"}},{"id":2300352,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":83059,"kind":"person","name":"Rovaldi Christopher","position":1,"cik":"0001706040","reported_name":"Rovaldi Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2022-04-08T16:21:01.000Z","date":"2022-04-06","kind":"sale","acquired":false,"shares":1728,"price":65,"value":112320.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-22-023860","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1706040/000120919122023860/doc4.xml","form_type":"4"}},{"id":2300351,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":83059,"kind":"person","name":"Rovaldi Christopher","position":1,"cik":"0001706040","reported_name":"Rovaldi Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2022-04-08T16:21:01.000Z","date":"2022-04-06","kind":"exercise","acquired":true,"shares":1728,"price":16,"value":27648.0,"ownership":{"direct":true},"balance_after":1728,"source":{"system":"sec-edgar","filing":"0001209191-22-023860","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1706040/000120919122023860/doc4.xml","form_type":"4"}},{"id":2304570,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":83059,"kind":"person","name":"Rovaldi Christopher","position":1,"cik":"0001706040","reported_name":"Rovaldi Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2022-04-05T16:31:59.000Z","date":"2022-04-01","kind":"exercise","acquired":false,"shares":864,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"One-fourth (1/4th) of the shares subject to the option vested on January 1, 2021, and one-twelfth (1/12th) of the remaining shares subject to the option shall vest in equal quarterly installments thereafter, subject to the Reporting Person continuing to provide service through each such date."}],"balance_after":9730,"derivative":{"exercise_price":16,"expiration_date":"2030-04-07","underlying":"Common Stock","underlying_shares":864},"source":{"system":"sec-edgar","filing":"0001209191-22-023037","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1706040/000120919122023037/doc4.xml","form_type":"4"}},{"id":2304569,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":83059,"kind":"person","name":"Rovaldi Christopher","position":1,"cik":"0001706040","reported_name":"Rovaldi Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2022-04-05T16:31:59.000Z","date":"2022-04-01","kind":"sale","acquired":false,"shares":105,"price":58.83,"value":6177.15,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $58.62 to $59.275 inclusive."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-22-023037","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1706040/000120919122023037/doc4.xml","form_type":"4"}},{"id":2304568,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":83059,"kind":"person","name":"Rovaldi Christopher","position":1,"cik":"0001706040","reported_name":"Rovaldi Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2022-04-05T16:31:59.000Z","date":"2022-04-01","kind":"sale","acquired":false,"shares":366,"price":57.97,"value":21217.02,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $57.58 to $58.26 inclusive."}],"balance_after":105,"source":{"system":"sec-edgar","filing":"0001209191-22-023037","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1706040/000120919122023037/doc4.xml","form_type":"4"}},{"id":2304567,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":83059,"kind":"person","name":"Rovaldi Christopher","position":1,"cik":"0001706040","reported_name":"Rovaldi Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2022-04-05T16:31:59.000Z","date":"2022-04-01","kind":"sale","acquired":false,"shares":287,"price":56.89,"value":16327.43,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $56.50 to $57.43 inclusive."}],"balance_after":471,"source":{"system":"sec-edgar","filing":"0001209191-22-023037","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1706040/000120919122023037/doc4.xml","form_type":"4"}},{"id":2304566,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":83059,"kind":"person","name":"Rovaldi Christopher","position":1,"cik":"0001706040","reported_name":"Rovaldi Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2022-04-05T16:31:59.000Z","date":"2022-04-01","kind":"sale","acquired":false,"shares":104,"price":56.2,"value":5844.8,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $55.50 to $56.23 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4) and (5)."}],"balance_after":758,"source":{"system":"sec-edgar","filing":"0001209191-22-023037","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1706040/000120919122023037/doc4.xml","form_type":"4"}},{"id":2304565,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":83059,"kind":"person","name":"Rovaldi Christopher","position":1,"cik":"0001706040","reported_name":"Rovaldi Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2022-04-05T16:31:59.000Z","date":"2022-04-01","kind":"sale","acquired":false,"shares":2,"price":54.34,"value":108.68,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan."}],"balance_after":862,"source":{"system":"sec-edgar","filing":"0001209191-22-023037","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1706040/000120919122023037/doc4.xml","form_type":"4"}},{"id":2304564,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":83059,"kind":"person","name":"Rovaldi Christopher","position":1,"cik":"0001706040","reported_name":"Rovaldi Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2022-04-05T16:31:59.000Z","date":"2022-04-01","kind":"exercise","acquired":true,"shares":864,"price":16,"value":13824.0,"ownership":{"direct":true},"balance_after":864,"source":{"system":"sec-edgar","filing":"0001209191-22-023037","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1706040/000120919122023037/doc4.xml","form_type":"4"}},{"id":2414069,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":83059,"kind":"person","name":"Rovaldi Christopher","position":1,"cik":"0001706040","reported_name":"Rovaldi Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2022-02-03T16:45:42.000Z","date":"2022-02-01","kind":"grant","acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One-fourth (1/4th) of the shares subject to the option shall vest on February 1, 2023, and one-twelfth (1/12th) of the remaining shares subject to the option shall vest in equal quarterly installments thereafter, subject to the Reporting Person continuing to provide service through each such date."}],"balance_after":100000,"derivative":{"exercise_price":49.34,"expiration_date":"2032-01-31","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001209191-22-006830","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1706040/000120919122006830/doc4.xml","form_type":"4"}},{"id":3970022,"issuer":{"id":15780,"kind":"organization","name":"ACCELERON PHARMA INC","symbol":"XLRN"},"owners":[{"id":83059,"kind":"person","name":"Rovaldi Christopher","position":1,"cik":"0001706040","reported_name":"Rovaldi Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Program Mgmt and Ops"}}],"security":"Common Stock","published_at":"2018-04-04T16:41:13.000Z","date":"2018-04-03","kind":"sale","acquired":false,"shares":600,"price":39.02,"value":23412.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.80 to $39.20 inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (4) to this Form 4."}],"balance_after":25858,"source":{"system":"sec-edgar","filing":"0001179110-18-005400","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1706040/000117911018005400/edgar.xml","form_type":"4"}},{"id":3970021,"issuer":{"id":15780,"kind":"organization","name":"ACCELERON PHARMA INC","symbol":"XLRN"},"owners":[{"id":83059,"kind":"person","name":"Rovaldi Christopher","position":1,"cik":"0001706040","reported_name":"Rovaldi Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Program Mgmt and Ops"}}],"security":"Common Stock","published_at":"2018-04-04T16:41:13.000Z","date":"2018-04-03","kind":"sale","acquired":false,"shares":2900,"price":38.27,"value":110983.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.78 to $38.63 inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 594 shares acquired pursuant to the Acceleron Pharma Inc. Employee Stock Purchase Plan on March 15, 2018."}],"balance_after":26458,"source":{"system":"sec-edgar","filing":"0001179110-18-005400","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1706040/000117911018005400/edgar.xml","form_type":"4"}},{"id":4015785,"issuer":{"id":15780,"kind":"organization","name":"ACCELERON PHARMA INC","symbol":"XLRN"},"owners":[{"id":83059,"kind":"person","name":"Rovaldi Christopher","position":1,"cik":"0001706040","reported_name":"Rovaldi Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Program Mgmt and Ops"}}],"security":"Option to Purchase Common Stock","published_at":"2018-03-05T17:16:35.000Z","date":"2018-03-01","kind":"grant","acquired":true,"shares":24375,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares of common stock underlying this stock option award vest in equal quarterly installments over the four years after January 1, 2018."}],"balance_after":24375,"derivative":{"exercise_price":40.61,"expiration_date":"2028-03-01","underlying":"Common Stock","underlying_shares":24375},"source":{"system":"sec-edgar","filing":"0001179110-18-003497","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1706040/000117911018003497/edgar.xml","form_type":"4"}},{"id":4015784,"issuer":{"id":15780,"kind":"organization","name":"ACCELERON PHARMA INC","symbol":"XLRN"},"owners":[{"id":83059,"kind":"person","name":"Rovaldi Christopher","position":1,"cik":"0001706040","reported_name":"Rovaldi Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Program Mgmt and Ops"}}],"security":"Common Stock","published_at":"2018-03-05T17:16:35.000Z","date":"2018-03-01","kind":"grant","acquired":true,"shares":4063,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":28764,"source":{"system":"sec-edgar","filing":"0001179110-18-003497","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1706040/000117911018003497/edgar.xml","form_type":"4"}},{"id":4098022,"issuer":{"id":15780,"kind":"organization","name":"ACCELERON PHARMA INC","symbol":"XLRN"},"owners":[{"id":83059,"kind":"person","name":"Rovaldi Christopher","position":1,"cik":"0001706040","reported_name":"Rovaldi Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Program Mgmt and Ops"}}],"security":"Option to Purchase Common Stock","published_at":"2018-01-17T17:14:20.000Z","date":"2018-01-12","kind":"exercise","acquired":false,"shares":11000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options of registrant's common stock vested in equal quarterly installments over the first four years after the grant."}],"balance_after":12000,"derivative":{"exercise_price":24.11,"expiration_date":"2023-12-05","underlying":"Common Stock","underlying_shares":11000},"source":{"system":"sec-edgar","filing":"0001179110-18-000920","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1706040/000117911018000920/edgar.xml","form_type":"4"}},{"id":4098021,"issuer":{"id":15780,"kind":"organization","name":"ACCELERON PHARMA INC","symbol":"XLRN"},"owners":[{"id":83059,"kind":"person","name":"Rovaldi Christopher","position":1,"cik":"0001706040","reported_name":"Rovaldi Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Program Mgmt and Ops"}}],"security":"Common Stock","published_at":"2018-01-17T17:14:20.000Z","date":"2018-01-12","kind":"sale","acquired":false,"shares":11000,"price":45,"value":495000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."}],"balance_after":24701,"source":{"system":"sec-edgar","filing":"0001179110-18-000920","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1706040/000117911018000920/edgar.xml","form_type":"4"}},{"id":4098020,"issuer":{"id":15780,"kind":"organization","name":"ACCELERON PHARMA INC","symbol":"XLRN"},"owners":[{"id":83059,"kind":"person","name":"Rovaldi Christopher","position":1,"cik":"0001706040","reported_name":"Rovaldi Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Program Mgmt and Ops"}}],"security":"Common Stock","published_at":"2018-01-17T17:14:20.000Z","date":"2018-01-12","kind":"exercise","acquired":true,"shares":11000,"price":24.11,"value":265210.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."}],"balance_after":35701,"source":{"system":"sec-edgar","filing":"0001179110-18-000920","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1706040/000117911018000920/edgar.xml","form_type":"4"}},{"id":4107735,"issuer":{"id":15780,"kind":"organization","name":"ACCELERON PHARMA INC","symbol":"XLRN"},"owners":[{"id":83059,"kind":"person","name":"Rovaldi Christopher","position":1,"cik":"0001706040","reported_name":"Rovaldi Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Program Mgmt and Ops"}}],"security":"Common Stock","published_at":"2018-01-04T19:05:21.000Z","date":"2018-01-03","kind":"sale","acquired":false,"shares":833,"price":42.45,"value":35360.85,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."}],"balance_after":24701,"source":{"system":"sec-edgar","filing":"0001179110-18-000549","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1706040/000117911018000549/edgar.xml","form_type":"4"}},{"id":4107734,"issuer":{"id":15780,"kind":"organization","name":"ACCELERON PHARMA INC","symbol":"XLRN"},"owners":[{"id":83059,"kind":"person","name":"Rovaldi Christopher","position":1,"cik":"0001706040","reported_name":"Rovaldi Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Program Mgmt and Ops"}}],"security":"Common Stock","published_at":"2018-01-04T19:05:21.000Z","date":"2018-01-02","kind":"sale","acquired":false,"shares":1433,"price":42.41,"value":60773.53,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.15 to $42.73 inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4."}],"balance_after":25534,"source":{"system":"sec-edgar","filing":"0001179110-18-000549","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1706040/000117911018000549/edgar.xml","form_type":"4"}},{"id":4209487,"issuer":{"id":15780,"kind":"organization","name":"ACCELERON PHARMA INC","symbol":"XLRN"},"owners":[{"id":83059,"kind":"person","name":"Rovaldi Christopher","position":1,"cik":"0001706040","reported_name":"Rovaldi Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Program Mgmt and Ops"}}],"security":"Common Stock","published_at":"2017-09-14T17:04:31.000Z","date":"2017-09-12","kind":"sale","acquired":false,"shares":100,"price":39.96,"value":3996.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."}],"balance_after":26967,"source":{"system":"sec-edgar","filing":"0001179110-17-012291","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1706040/000117911017012291/edgar.xml","form_type":"4"}},{"id":4209486,"issuer":{"id":15780,"kind":"organization","name":"ACCELERON PHARMA INC","symbol":"XLRN"},"owners":[{"id":83059,"kind":"person","name":"Rovaldi Christopher","position":1,"cik":"0001706040","reported_name":"Rovaldi Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Program Mgmt and Ops"}}],"security":"Common Stock","published_at":"2017-09-14T17:04:31.000Z","date":"2017-09-12","kind":"sale","acquired":false,"shares":1165,"price":39.3,"value":45784.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.85 to $39.82 inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4."}],"balance_after":27067,"source":{"system":"sec-edgar","filing":"0001179110-17-012291","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1706040/000117911017012291/edgar.xml","form_type":"4"}},{"id":4209485,"issuer":{"id":15780,"kind":"organization","name":"ACCELERON PHARMA INC","symbol":"XLRN"},"owners":[{"id":83059,"kind":"person","name":"Rovaldi Christopher","position":1,"cik":"0001706040","reported_name":"Rovaldi Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Program Mgmt and Ops"}}],"security":"Common Stock","published_at":"2017-09-14T17:04:31.000Z","date":"2017-09-12","kind":"sale","acquired":false,"shares":12735,"price":38.32,"value":488005.2,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.78 to $38.77 inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4."}],"balance_after":28232,"source":{"system":"sec-edgar","filing":"0001179110-17-012291","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1706040/000117911017012291/edgar.xml","form_type":"4"}}]}